nce these and other stem cell projects in crucial ways, said Goldstein, accelerating their movement into clinical trials with patients. The Center will deepen the connection with stem cell research partners in San Diego
, allowing them to collaborate with one of the country's leading academic medical centers. It will establish the best standards in stem cell testing, safety and efficacy. It will effectively tackle the necessary regulatory requirements. All of these efforts, Goldstein said, are critical to speeding experimental therapies to use by patients.
"This significant philanthropic gift from Mr. Sanford, combined with funding from CIRM and elsewhere, puts UC San Diego in a unique and advantageous position," noted David A. Brenner, MD, vice chancellor for Health Sciences and dean of the UC San Diego School of Medicine. "We are the only academic medical institution in the region with the scientists, physicians, facilities and clinical delivery system to bring the promise of stem cell therapies to fruition. No place in the world has a better chance of success."
Sanford's donation is the latest in a history of philanthropic largess. In his lifetime, he has given more than $1 billion, primarily to health- and children-related causes, often in his native state of South Dakota. In 2007, for example, he announced a $400 million gift to the Sioux Valley Hospitals and Health System for various health care and research initiatives.
In San Diego, Sanford and his foundation donated $20 million to the Burnham Institute for Medical Research in 2007 and issued a $50 million challenge grant three years later to the renamed Sanford-Burnham Medical Research Institute.
Sanford, 77, resides in Sioux Falls, South Dakota, with vacation homes in Arizona, California and
Page: 1 2 3 4 5 Related biology technology :1
|SOURCE University of California, San Diego|
Copyright©2012 PR Newswire.
All rights reserved
. Spherix Announces Private Placement as the Company Continues to Execute its Patent Monetization Program - Spherix accepts $2.0 Million from Investors2
. Discovery Labs Prices $50 Million Public Offering of Common Stock3
. PathoGenetix Announces $10 Million Series C Financing4
. Immune Design Raises Up to $49 Million Series C Financing5
. CryoLife Third Quarter 2013 Revenues Increase 8 Percent to a Record $36.3 Million6
. Genufood Energy Enzymes Corp. Announces $20 Million Equity Purchase Agreement7
. NextCODE Health Launches Operations with Exclusive License to Leverage deCODE genetics Genomics Platform for Sequence-Based Clinical Diagnostics, and $15 Million in Venture Financing8
. Sigma-Aldrich (NASDAQ: SIAL) Reports Q3 2013 Sales Of $664 Million, Organic Sales Growth Of 5% And Adjusted Diluted EPS Of $1.05. Reaffirms Full Year 2013 Organic Sales Outlook. Narrows Adjusted Diluted EPS Outlook To A New Range Of $4.08 To $4.159
. Claritas Genomics to Sequence Exomes for VA Million Veteran Program with Ion Torrent Next-Generation Sequencers10
. Croda Inc Unveils $2.3 Million Investment in Solar11
. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing